Genomic Damage in Non-Small-Cell Lung Cancer
Author Information
Author(s): C de Juan, P Iniestal, FJ Vega, MA Peinado, C Fernandez, T Caldes, M Jose Massa, JA López, A Sanchez, AJ Torres, JL Balibrea, M Benito
Primary Institution: Universidad Complutense, Madrid, Spain
Hypothesis
Does genomic damage affect patient survival in non-small-cell lung cancer?
Conclusion
High genomic damage in non-small-cell lung cancer patients is associated with poorer prognosis.
Supporting Evidence
- Patients with high genomic damage showed a poorer prognosis than those with low or moderate genomic damage.
- Multivariate analysis indicated that high genomic damage was associated with a risk ratio 4.26 times higher than other patients.
- 64% of genomic changes detected were gains in genomic sequences.
Takeaway
This study found that patients with more genomic damage in their lung cancer have a worse chance of survival.
Methodology
Genomic alterations were analyzed in 65 non-small-cell lung cancer tissue samples using arbitrarily primed polymerase chain reaction (AP-PCR).
Limitations
The study only included patients with stages I, II, and IIIA tumors, excluding those with more advanced stages.
Participant Demographics
64 men and 1 woman, median age 62.2 years.
Statistical Information
P-Value
0.038
Confidence Interval
95% CI = 1.03-17.54
Statistical Significance
p=0.038
Want to read the original?
Access the complete publication on the publisher's website